Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Georgia Fogden-King's Articles

The CLASP Healthcare call has £2m to fund a small number of projects ranging from short feasibility studies to larger developmental projects

The proposals led by eligible STFC scientists will provide solutions to address the healthcare grand challenges using STFC science, technologies and skills. User engagement is encouraged.  

Replimune Appoints Howard L. Kaufman, M.D., FACS as Chief Medical Officer

Replimune Group Inc. announced today a key addition to its senior leadership team as it progresses its Immulytic™ oncolytic immunotherapy platform rapidly towards clinical trials.

Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs

Biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing.

Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases

$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV

AMSBIO has announced a new range of CD47-relevant products suitable for rapid high throughput screening studies.

 The new AMSBIO CD47 protein kits are supplied as pairs of products that can be easily adapted to ELISA, AlphaLISA™ and MSD platforms to facilitate rapid and easy screening of the neutralizing compound.

Wireless technology breathes new life into medical practices

A leading clinician of a top UK children’s hospital believes wireless monitoring is changing the face of healthcare.

Invicro Acquires Imanova to Expand Global Imaging Capabilities

Combined business delivers world-leading imaging capabilities to drive improved decision-making from early drug discovery to late-phase clinical development

Speculative 110,000 sq ft office and laboratory Development reaches key milestone on at Milton Park, Oxfordshire

Construction work at the £24m Park Drive East development at Milton Park being undertaken by MEPC has reached the half way milestone

Novartis gene therapy approval signals new cancer treatment era

Novartis AG won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers.

Gilead buys into CAR-T with $11.9bn deal for Kite

Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.